Summary: In this ebook, read how matching up with the right partner can help you seize the opportunities and assemble the foundation for a successful first-in-humans study

Summary: Catalent's Biologics site in Bloomington, Indiana provides a drug substance manufacturing area that includes production bioreactors ranging from 200 L single-use to 2,500 L stainless steel.

Summary: In this podcast, experts discuss how to overcome obstacles that span from discovery to launch of orphan drugs as well as discuss the needs of patients and drug developers in orphan biologics development.

Summary: A scalable, CGMP-ready process for viral vector manufacturing that reduces the current 18-20-month development timeline for drug product in half.

Summary: Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population.

Summary: The field’s top experts weigh in on the technologies they are working on, including self-amplifying RNA, computer-designed nanoparticles, expanding mRNA processes and...

Summary: Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies.

Summary: In this webinar, experts discuss the formulation development challenges, considerations, and potential solutions associated with...

Summary: In this podcast, we will discuss how Catalent is working to simplify the supply chain, develop processes scalable for late-stage and commercial needs, and accelerate timelines for production of clinical materials.

Summary: During this session, we review progress in several areas of advanced development and their impact on readiness for large scale manufacturing.